Does imatinib change the outcome in philapdelphia chromosome positive acute lympooblastic leukaemia in adults? Data from the UKALLXII/ECOG2993 study

Παρόμοια τεκμήρια

• Imatinib Significantly Enhances Long-Term Outcomes In Philadelphia Positive Acute Lymphoblastic Leukaemia; Final Results of the UKALLXII/ECOG2993 Trial
  ανά: Fielding, A, κ.ά.
  Έκδοση: (2010)
• Imatinib Significantly Enhances Long Term Outcomes In Philadelphia Positive Acute Lymphoblastic Leukaemia, Final Results of the UKALLXII/ECOG2993 Trial
  ανά: Fielding, A, κ.ά.
  Έκδοση: (2010)
• Imatinib Significantly Enhances Long Term Outcomes In Philadelphia Positive Acute Lymphoblastic Leukaemia, Final Results of the UKALLXII/ECOG2993 Trial
  ανά: Fielding, A, κ.ά.
  Έκδοση: (2010)
• UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia.
  ανά: Fielding, A, κ.ά.
  Έκδοση: (2014)
• At three years, patients with acute lymphoblastic leukaemia are still at risk for relapse. Results of the international MRC UKALLXII/ECOG E2993 trial
  ανά: Ganzel, C, κ.ά.
  Έκδοση: (2020)